BioSpace News Archive

Ligand Pharmaceuticals Incorporated and Agenus Inc. announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company’s long-time institutional investors, with gross proceeds of $11.6 million, bringing the total Series B / B-1 gross proceeds to $29.8 million.

One year since forming its Advisory Board, Lokavant, the clinical trial intelligence platform company, announces three new members, including Pfizer’s Head of Predictive Analytics Jonathan Crowther.

BioAtla, Inc. announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights.

BioStem Technologies Inc., a leading biotechnology company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, announced that it plans to release its first quarter 2024 financial results post-market on Tuesday, May 14, 2024.

Ardelyx, Inc. announced that additional data supporting IBSRELA® will be presented at the 2024 Digestive Disease Week Conference, to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation in adults.

Daré Bioscience, Inc., a leader in women’s health innovation, announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2024, to review its financial results for the quarter ended March 31, 2024 and to provide a company update.

Corbus Pharmaceuticals Holdings, Inc., a precision oncology company with a diversified portfolio, provided a corporate update and reported financial results for the quarter ended March 31, 2024.

Eterna Therapeutics Inc., a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, announced that Elizabeth Belcher will present a poster at the 27th Annual Meeting of the American Society of Gene & Cell Therapy.

Eterna Therapeutics Inc. announces that Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene & Cell Therapy, taking place in Baltimore, Maryland.